Vascular endothelial growth factor (VEGF) inhibitor, Eydenzelt (aflibercept-boav), is now approved to treat retinal disease ...

Eydenzelt is a vascular endothelial growth factor inhibitor referencing Eylea, which is jointly developed by Regeneron ...

The Food and Drug Administration (FDA) has approved Eydenzelt ® (aflibercept-boav), a biosimilar to Eylea ® (aflibercept).

Developing cardiac inflammatory organoid models incorporating multiple cell lineages is vital for novel therapies.

Using all-atom simulations of model mycomembranes, the work reports compelling structural insights into how α-mycolic acids and outer leaflet lipids (PDIM and PAT) shape membrane organisation. The ...

Can Pfizer’s GDF15-blocking, appetite-boosting antibody ponsegromab address a cancer-induced wasting syndrome — and help ...

Objective To clarify whether atherogenic index of plasma (AIP), a comprehensive indicator reflecting both the protective and ...